Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US NQF (National Quality Forum) report to prompt national event reporting?:

This article was originally published in Clinica

Executive Summary

A report issued last month by the National Quality Forum (NQF) could form the basis of a new US system for reporting adverse events in healthcare. "Wrong-site surgery, medication errors and infant discharges to the wrong person occur more frequently than the public would like to believe," says the Washington-based NQF's president, Kenneth Kizer. Six main categories of event are identified in the report, including product/device events and surgical events. Into these six groups fit 27 actual individual events. Dr Kizer hopes this provides the platform for other interested parties to contribute, possibly expanding the list into what could be become the basis for a national, state-based adverse event reporting system. Details at: www.qualityforum.org

You may also be interested in...



EU Turns Up Heat On PFAS With Broad REACH Restriction Proposal In The Works

Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Topics

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel